Soligenix (NASDAQ: SNGX) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Institutional and Insider Ownership
2.1% of Soligenix shares are held by institutional investors. Comparatively, 33.5% of XOMA shares are held by institutional investors. 5.0% of Soligenix shares are held by company insiders. Comparatively, 3.0% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Soligenix and XOMA’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings & Valuation
This table compares Soligenix and XOMA’s revenue, earnings per share and valuation.
||Earnings Per Share
Soligenix has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Soligenix and XOMA, as provided by MarketBeat.com.
||Strong Buy Ratings
Soligenix currently has a consensus target price of $5.25, suggesting a potential upside of 157.35%. XOMA has a consensus target price of $28.50, suggesting a potential downside of 1.42%. Given Soligenix’s stronger consensus rating and higher possible upside, equities analysts clearly believe Soligenix is more favorable than XOMA.
Risk and Volatility
Soligenix has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, XOMA has a beta of 3.19, meaning that its stock price is 219% more volatile than the S&P 500.
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.